Ophthalmic disodium cromoglycate.

Abstract

Disodium cromoglycate has recently been approved for ophthalmic treatment of certain types of conjunctivitis in the United States. This mast cell inhibitor is effective in the treatment of vernal keratoconjunctivitis, allergic conjunctivitis, chronic conjunctivitis, and giant papillary conjunctivitis, especially when a history of atopic disorders or moderately low blood IgE levels are present. This literature review provides a foundation for understanding the balance between the therapeutic efficacy, clinical benefits and side effects in treating IgE-mediated conjunctivitis with disodium cromoglycate.

• Authors: D W Tierney
• Journal: Journal of the American Optometric Association (J Am Optom Assoc) Vol. 56 Issue 12 Pg. 928-31 (Dec 1985) ISSN: 0003-0244 [Print] United States
• PMID: 3937847 (Publication Type: Journal Article)

Chemical References

• Cromolyn Sodium

Topics

• Chronic Disease
• Conjunctivitis, Allergic (drug therapy)
• Cromolyn Sodium (adverse effects, therapeutic use)
• Humans
• Keratoconjunctivitis (drug therapy)